Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update

dnrt8765

TORRANCE, Calif.–(BUSINESS WIRE)–Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update.

“We are very happy to have concluded the reverse merger on June 15th and in that process, brought on a very well-respected group of investors, including Alger, BVF Partners, Franklin Templeton and OrbiMed to support Forte as we continue to grow the company. Our lead program, FB-401, developed in collaboration with the National Institute of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), has shown

Melange by Lifestyle announces Deepika Padukone as brand ambassador, launches ‘Work from Home’ collection

dnrt8765

Ethnic wear brand Melange by Lifestyle announced actor and style icon Deepika Padukone as its brand ambassador, and launched a new collection. This collaboration strengthens the brand ethos of ‘Rethink Ethnic’ and epitomises the versatile, eclectic style of modern Indian women.

Call for entries open for BuzzInContent Awards 2020 ENTER NOW

Comprising key trends, quintessential season favourites, and contemporary styles and silhouettes, the curated collection is an absolute delight for customers. The ever-popular ‘florals’ has been re-imagined in new silhouettes and prints. The ‘Work from Home’ collection featuring the linen range brings together fashion and utility. Traditional paisley has been

Kaskela Law LLC Announces Investigation of FirstEnergy Corp. (FE) and Encourages Long-Term FE Stockholders to Contact the Firm

dnrt8765

PHILADELPHIA, Aug. 10, 2020 /PRNewswire/ — Kaskela Law LLC announces that it is investigating FirstEnergy Corp. (“FirstEnergy”) (NYSE: FE) on behalf of the company’s stockholders.  The investigation seeks to determine whether the members of FirstEnergy’s board of directors breached their fiduciary duties to FirstEnergy and its stockholders. 

Current FirstEnergy stockholders who purchased or acquired shares of the company’s stock prior to February 21, 2017 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (484) 258 – 1585, or online at http://kaskelalaw.com/case/firstenergy-corp/, to discuss this investigation and their legal rights and options with respect to

Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights

dnrt8765

PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2020.

“We have made strong progress across the entire company this quarter— clinical, manufacturing, research and corporate. I am very proud of how our growing Kodiak community has continued to execute in the midst of the ongoing global pandemic,” said Victor Perlroth, MD, Chief Executive Officer of Kodiak. “There is a high unmet need